Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate that has been approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Despite the remarkable efficacy of T-DM1 in many patients, resistance to this therapeutic has emerged as a significant clinical problem. In the current study, we used BT-474/KR cells, a T-DM1-resistant cell line established from HER2-positive BT-474 breast cancer cells, as a model to investigate mechanisms of T-DM1 resistance and explore effective therapeutic regimens.
| INTRODUCTION
Breast cancer is the most common cancer in women worldwide, and the prognosis for patients with this disease is poor. 1 Human epidermal growth factor receptor 2 (HER2) is amplified in up to 20% of primary breast cancers and is associated with aggressive tumor features. 2 The anti-HER2 monoclonal antibodies trastuzumab and pertuzumab, as well as the kinase inhibitor lapatinib, which targets epidermal growth factor receptor (EGFR) and HER2, have been approved for HER2-positive breast cancer and have been shown to provide clinical benefits, 3, 4 but primary and acquired resistance to these drugs is common. surface, the HER2-T-DM1 complex enters the cell via receptormediated endocytosis. 6, 7 DM1 is then released from lysosomes and inhibits microtubule assembly, causing mitotic arrest and apoptosis. 8, 9 T-DM1 is recommended in the clinic as a second-line treatment for HER2-positive, advanced breast cancer that has progressed during or after first-line HER2-targeted therapy (trastuzumab, pertuzumab, or taxane). 10 Although the clinical results with T-DM1 are impressive, some patients do not respond to the drug or relapse after an initial response. 11 Unlike mechanisms underlying resistance to trastuzumab, pertuzumab or lapatinib, which are generally well understood, however, the mechanisms responsible for T-DM1 resistance are poorly characterized. Among the known mechanisms of T-DM1 resistance are hindrance of trastuzumab binding to HER2
caused by mucin 4 (MUC4) expression, 12 defects in intracellular metabolism of T-DM1 owing to impaired lysosomal proteolytic activity, 13, 14 and efflux of DM1 as a result of the expression of multidrug resistance (MDR) transporters. 15, 16 Clearly, additional effort is required to understand and overcome T-DM1 resistance.
To address this problem, we modeled the development of acquired resistance in patients by establishing the monoclonal T-DM1-resistant cell line, BT-474/KR, from parental HER2-overexpressing BT-474 human breast cancer cells. Using this model, we sought to gain a better understanding of the mechanisms that confer T-DM1 resistance, and, more importantly, to develop effective regimens to overcome this resistance.
| MATERIALS AND METHODS

| Reagents and antibodies
The T-DM1 and trastuzumab were purchased from F. Hoffmann-La Roche (Basel, Switzerland). Napabucasin and DM1 were purchased 
| Cell culture and treatment
The human BT-474 and MDA-MB-231 cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured according to instructions provided by the ATCC.
The human KB and KBV200 cell lines were kindly provided by Professor Liwu Fu (Sun Yat-sen University, Guangzhou) and were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum. Acquired T-DM1-resistant cells (BT-474/KR) were established by exposing parental BT-474 cells to increasing concentrations of T-DM1 (from 10 ng/mL to 1 μg/mL) for 12 months and selecting clones through the limiting dilution method.
| Cell proliferation assay
Cell growth inhibition was determined using a sulforhodamine B assay, as described previously. 17 Briefly, approximately 24 hours after plating, cells were treated with different concentrations of drugs, alone or in combination, as indicated. At least 3 independent experiments were performed, and results are presented as mean ± SD.
| Western blot analysis
Cells were lysed in sodium dodecyl sulfate (SDS) sample buffer and boiled for 10 minutes. Western blot analysis was conducted as previously described, 17 and the levels of cellular proteins were visualized using the Western blot Imaging System (Clinx Science Instruments, Shanghai, China). Results were quantified on densitometry and normalized to β-tubulin level.
| RNA isolation and quantitative reverse transcription-polymerase chain reaction
The RNA was isolated using the TRIzol reagent system and reverse transcribed using the PrimeScript Reverse Transcription reagent Kit ACT-3′ (reverse); GAPDH, 5′-GGG GAA GGT GAA GGT CGG AGT C-3′ (forward) and 5′-CAA GCT TCC CGT TCT CAG CCT T-3′ (reverse). mRNA was quantified using the 2 −ΔΔCT method, and target mRNA level was normalized to those of the housekeeping gene, GAPDH.
| Cell cycle analysis
Cells were fixed in ethanol and stained with propidium iodide (PI) following standard methods. The cell cycle was analyzed on fluorescence-activated cell sorting (FACS) using a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA).
| Polymeric tubulin fraction assay
Polymeric tubulin was determined as described previously. 18 Briefly, cells were lysed by incubating with a buffer consisting of 80 mmol/L MES-KOH (pH 6.8), 1 mmol/L MgC1 2 , 1 mmol/L EGTA, 0.1% Triton X-100 and 10% glycerol for 3 minutes at 30°C, after which detergent-insoluble polymerized cytoskeleton was measured on western blotting.
| Binding assay
Cells were incubated with DyLight 488 NHS-ester-linked T-DM1 (1 μg/ mL) on ice for 1 hour and analyzed for binding affinity on flow cytometry.
| Endocytosis assay
Cells were incubated with DyLight 488 NHS-ester-linked T-DM1
(1 μg/mL) in growth medium at 37°C and then incubated on ice for siSTAT3#1, 5′-CCA CUU UGG UGU UUC AUA A-3′; siSTAT3#2, 5′-GGA GAA GCA UCG UGA GUG A-3′; siLIFR#1, 5′-CCA CAC CGC UCA AAU GUU A-3′; siLIFR#2, 5′-GAA CAA AAC GUU UCC UUA A-3′.
| ELISA
Cells were seeded in 6-well plates at 10 6 cells per well. After 96 hours, the supernatants were collected. IL-6 secretion was evaluated with enzyme-linked immunosorbent assay (ELISA) kit (Dakewe Biotech, Shenzhen, China) according to the manufacturer's instructions. The absorbance was read at 450 nm.
| Clonogenic assay
Cells were seeded in 6 
| Immunohistochemistry
Immunohistochemistry was conducted as previously described. 17 LIFR-positive sites were visualized using a SABC kit and a DAB kit.
| Statistical analysis
Data were analyzed using GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA). Non-linear regression analysis was performed to generate dose-response curves and calculate 50% inhibitory concentration (IC 50 ). Two-tailed Student's t test was used to determine the statistical significance of differences between 2 groups. P < .05 was considered statistically significant. 
| T-DM1 trafficking, microtubule dynamics, and drug efflux are not involved in T-DM1 resistance in BT-474/KR cells
The drug release mechanism for T-DM1 consists of several key steps, including binding to HER2, internalization into cells, and release of DM1 through degradation of the T-DM1 conjugate. 19 Factors that affect these steps could conceivably play a role in T-DM1 resistance.
To test this, we first assessed HER2 status in BT-474/KR cells. As shown in Figure 
| LIFR overexpression induces STAT3 activation in BT-474/KR cells
The STAT signaling is mainly activated by growth factor receptors and cytokine receptors in the plasma membrane. 24 LIFR and aberrant STAT3 activation, we knocked down LIFR using 2 independent siRNAs. siRNA-mediated LIFR knockdown significantly inhibited STAT3 activation ( Figure 5C ) and sensitized BT-474/KR cells to T-DM1 treatment ( Figure 5D ). Collectively, this suggests that T-DM1 resistance is due, at least in part, to overexpression of LIFR and subsequent STAT3 activation.
| Factors secreted by BT-474/KR cells confer resistance in BT-474 cells
Signal transducer and activator of transcription 3 induces the expression of several cytokines and growth factors. Given that IL-6 is a well-known factor induced by STAT3, 24 we analyzed IL-6 expression as an indicator. On analysis of IL-6 secretion on ELISA ( Figure 6A) and of IL-6 mRNA on real-time PCR (Figure 6B ), IL-6 was increased 
| STAT3 inhibition overcomes T-DM1 resistance in vivo
To extend these in vitro findings to an in vivo setting, we further performed xenograft studies. We first verified that the LIFR-STAT3 
| DISCUSSION
Trastuzumab-emtansine shows remarkable activity in HER2-positive breast cancers, but drug resistance inevitably occurs after long-term treatment in most patients, highlighting the importance of understanding the mechanism underlying resistance to T-DM1 and of developing new strategies to overcome it. Here, we modeled the development of acquired resistance in patients using the T-DM1- The LIF/LIFR axis is involved in a variety of biological responses, including growth promotion, cell differentiation, bone metabolism, and inflammation. 28 Unlike receptor tyrosine kinases, LIFR is not self-activated; its activation requires ligands such as LIF, ciliary neurotrophic factor, oncostatin M, cardiotrophin 1, and cardiotrophin-like cytokine. 29 On kinetic analysis, LIF-LIFR interactions exhibit a near diffusion-limited on-rate and an extremely slow off-rate, suggesting that the amount of LIFR expressed is the rate-limiting factor for this process. 30, 31 Notably, there is a growing appreciation of the importance of LIFR upregulation in limiting the potency of targeted therapies. For example, a recent study found that feedback activation of LIFR limits the response to histone deacetylase inhibitors in breast cancer. 31 The present study adds to evidence supporting LIFR involvement in mediating resistance by demonstrating that overexpression of LIFR leads to STAT3 activation and confers resistance to T-DM1 in HER2-positive breast cancer cells. LIFR expression is regulated by many complex mechanisms, such as gene copy number changes, histone acetylation or methylation at the LIFR gene promoter, microRNA and so on. [31] [32] [33] We found that the gene copy number of LIFR was not changed in BT-474/KR cells ( Figure S1 ), and the exact mechanisms underlining LIFR overexpression in BT-474/KR cells needed further research.
Increasing evidence supports the critical role of STAT3 signaling in drug resistance. STAT3 activation upregulates several anti-apoptotic proteins, including Bcl-xL, Bcl-2, survivin and Mcl-1, and leads to apoptosis resistance. 34 STAT3 activation was also found in HER2-overexpressing breast cancer to promote epithelial-mesenchymal transition (EMT) and cancer stem cell traits. 35 Aberrant STAT3 activation has been implicated in trastuzumab resistance in HER2-positive breast and gastric cancers. 36 Moreover, STAT3 is involved in resistance to antimicrotubule agents, and the combination of taxane and a STAT3 inhibitor was showed to exert enhanced cytotoxicity towards STAT3-dependent cell lines. 37, 38 The present study first showed that STAT3 is aberrantly activated in cells exposed to long- Many STAT3-regulated genes encode cytokines and growth factors, 24 which in turn activate STAT3, promote cancer progression, and confer resistance to chemotherapeutic treatments. 39 We found reported to promote tumor growth. 24 The mechanisms include direct effects of secreted factors on cancer cells, for example, promoting cancer cell survival, regulating the self-renewal of cancer stem cells, and inducing an EMT, 40 and indirect effects, for example, promoting tumor angiogenesis, 41 and perturbing immunosurveillance. 42 In clinic, high IL-6 has been correlated with poor survival in breast cancer patients, including those with HER2-amplified breast tumors. 43 Cancer cells are extremely heterogeneous, even in the same tumor. 44 The present study has shown that, in a heterogeneous breast tumor, resistant cells with activated STAT3 might confer acquired resistance to originally sensitive cells by secreting cytokines and growth factors.
In conclusion, we report a novel mechanism in which LIFR over- combining T-DM1 with STAT3-targeted therapy could be a promising treatment strategy for HER2-positive breast cancer that progresses after T-DM1.
